$293 Million is the total value of RTW INVESTMENTS, LP's 35 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 26.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALNY | Sell | Alnylam Pharmaceuticals Inc | $46,198,000 | -15.1% | 832,549 | -3.9% | 15.78% | -20.1% |
| INCY | Buy | Incyte Corp | $31,371,000 | +14.1% | 392,236 | +3.4% | 10.72% | +7.4% |
| BLUE | Buy | bluebird bio Inc | $26,495,000 | +175.4% | 612,025 | +170.4% | 9.05% | +159.1% |
| ACHN | Sell | Achillion Pharmaceuticals Inc | $18,908,000 | -4.3% | 2,424,136 | -5.3% | 6.46% | -9.9% |
| LJPC | Buy | La Jolla Pharmaceutical Co | $18,818,000 | -23.0% | 1,176,146 | +0.6% | 6.43% | -27.6% |
| AVXS | Buy | Avexis Inc | $18,111,000 | +40.4% | 476,367 | +0.6% | 6.19% | +32.2% |
| BMY | Buy | Bristol-Myers Squibb Co | $15,424,000 | +120.1% | 209,701 | +91.2% | 5.27% | +107.2% |
| KITE | Sell | Kite Pharma Inc | $14,276,000 | -9.5% | 285,518 | -16.9% | 4.88% | -14.8% |
| SSRG | Buy | Symmetry Surgical Inc | $12,109,000 | +33.5% | 922,215 | +0.3% | 4.14% | +25.7% |
| GLD | New | SPDR Gold Shares ETF | $10,497,000 | – | 83,000 | +100.0% | 3.59% | – |
| ATRA | Sell | Atara Biotherapeutics Inc. | $10,487,000 | +16.5% | 465,874 | -1.5% | 3.58% | +9.6% |
| AGEN | Buy | Agenus Inc | $9,838,000 | -2.1% | 2,429,149 | +0.6% | 3.36% | -7.8% |
| BCRX | Buy | BioCryst Pharmaceuticals Inc | $6,353,000 | +13.7% | 2,237,066 | +13.3% | 2.17% | +7.1% |
| TLT | Buy | iShares 20+ Year Treasury Bond ETF20 yr tr bd etf | $6,251,000 | +59.5% | 45,000 | +50.0% | 2.14% | +50.2% |
| DRNA | Dicerna Pharmaceuticals Inc | $6,081,000 | -44.0% | 2,026,894 | 0.0% | 2.08% | -47.3% | |
| ICPT | New | Intercept Pharmaceuticals Inc | $5,636,000 | – | 39,500 | +100.0% | 1.93% | – |
| CLDX | Buy | Celldex Therapeutics Inc | $5,550,000 | +48.4% | 1,264,227 | +27.8% | 1.90% | +39.6% |
| OMER | Sell | Omeros Corp | $5,542,000 | -59.5% | 526,788 | -40.9% | 1.89% | -61.9% |
| VIVE | New | Viveve Medical Inc | $3,341,000 | – | 814,946 | +100.0% | 1.14% | – |
| JJOFF | New | Barclays Bank iPath Dow Jones-UBS Coffee Subindex TR ETNetn djubscoffe38 | $3,194,000 | – | 144,200 | +100.0% | 1.09% | – |
| CORI | Buy | Corium International Inc | $2,960,000 | -7.4% | 852,961 | +3.0% | 1.01% | -12.9% |
| IVTY | Buy | Invuity Inc | $2,154,000 | +40.2% | 226,042 | +6.2% | 0.74% | +31.9% |
| RGNX | Buy | Regenxbio Inc | $1,942,000 | -25.5% | 242,784 | +0.6% | 0.66% | -29.9% |
| FPRX | Sell | Five Prime Therapeutics Inc | $1,848,000 | -80.0% | 44,701 | -80.3% | 0.63% | -81.2% |
| GBT | Sell | Global Blood Therapeutics Inc | $1,612,000 | -46.8% | 97,138 | -49.1% | 0.55% | -49.9% |
| MASI | Masimo Corp | $1,360,000 | +25.5% | 25,900 | 0.0% | 0.46% | +18.0% | |
| AXDX | Sell | Accelerate Diagnostics Inc | $1,077,000 | -36.0% | 74,843 | -36.1% | 0.37% | -39.8% |
| CYTR | Sell | CytRx Corp | $1,040,000 | -24.4% | 466,200 | -9.1% | 0.36% | -28.9% |
| SRTSU | New | Sensus Healthcare Incunit 99/99/9999 | $1,006,000 | – | 155,000 | +100.0% | 0.34% | – |
| MNKD | MNKD 01/20/2017 PUT 3put | $912,000 | +1.4% | 4,385 | 0.0% | 0.31% | -4.3% | |
| MRTX | Sell | Mirati Therapeutics Inc | $716,000 | -92.2% | 131,052 | -69.4% | 0.24% | -92.6% |
| MDRX | Allscripts Healthcare Solutions Inc | $610,000 | -3.8% | 48,000 | 0.0% | 0.21% | -9.6% | |
| BPMX | Biopharmx Corp | $455,000 | -40.4% | 700,636 | 0.0% | 0.16% | -44.0% | |
| NTRA | Natera Inc | $382,000 | +26.5% | 31,693 | 0.0% | 0.13% | +19.1% | |
| NVLS | Nivalis Therapeutics Inc | $138,000 | +10.4% | 30,000 | 0.0% | 0.05% | +4.4% | |
| BRKB | Exit | Berkshire Hathaway Inccl b new | $0 | – | -50 | -100.0% | -0.00% | – |
| NVRO | Exit | NVRO 05/20/2016 PUT 50put | $0 | – | -142 | -100.0% | -0.01% | – |
| ADAP | Exit | Adaptimmune Therapeutics-adrsponds adr | $0 | – | -7,691 | -100.0% | -0.02% | – |
| LPCN | Exit | Lipocine Inc | $0 | – | -240,438 | -100.0% | -0.89% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.